Skip to main content

Mobilising the European nano-biomedical ecosystem

Periodic Reporting for period 1 - NOBEL (Mobilising the European nano-biomedical ecosystem)

Reporting period: 2017-10-01 to 2019-03-31

While NOBEL follows the main goal of shaping and implementing a strategic vision for HealthTech in Europe, several priorities will be addressed by the partners:
1. improving awareness and communication among all healthcare stakeholders in Europe,
2. establishing a structured collaboration between different stakeholder communities to create a functional and sustainable ecosystem,
3. continuing and optimising Translation & Acceleration tools for innovative projects in HealthTech. It will thereby further expand the successful concept of the Nanomedicine Translation HUB designed by the ETPN, a global set of tools among which the Nanomed TAB for strategic mentoring, the EU-NCL for characterisation and pilot lines,
4. aligning and integrating individual and separate strategies and roadmaps into a single “meta” roadmap for healthcare technologies in Europe.

- A challenging context -
Europe has to innovate and develop nanomedicines and medical technologies with high value and high technological content, well protected IP, and ensuring both a clinical need and commercial opportunities of all new innovations.
This can only be achieved by combining Key Enabling Technologies (KETs), among others nanotechnologies, photonics, robotics, advanced materials, information technologies to get smarter medical devices and smarter nanomedicines.
However, the translation from the preclinical proof of concepts toward the market requires a more integrated and streamlined ecosystem with less barriers between stakeholders and steps.
By building a coherent, robust and unique ecosystem, NOBEL partners improve the information flow and increase awareness all along the value chain. Furthermore, a functioning ecosystem requires both a common vision and strategy to concretely shape the future and a high cohesion and interrelationship among the different stakeholders. NOBEL develop these instruments to foster interactions and cooperation and implement complementary actions at local, regional, national, European and even international levels for an optimal coverage and increased impact.
1. Increased take-up of innovative nanomedicine and emerging medical technologies solutions by industry and SMEs, end-users, regulatory and public authorities, healthcare insurances, doctors and patients, research organisations and academia
2. Improvement of cross-KETs activities to provide better integrated smart healthcare solutions
3. Increased international networking with new potential market opportunities
4. Global Improvement of the competitiveness of the European healthcare sector
NOBEL logo